| scholarly article | Q13442814 |
| P2093 | author name string | Yoshifumi Saisho | |
| P2860 | cites work | Insulin use and increased risk of mortality in type 2 diabetes: a cohort study | Q51612089 |
| Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese Type II diabetic patients | Q53979441 | ||
| Endothelial insulin receptor expression in human atherosclerotic plaques: Linking micro- and macrovascular disease in diabetes? | Q54529195 | ||
| Does diabetes therapy influence the risk of cancer? | Q54732953 | ||
| U.K. prospective diabetes study 16. Overview of 6 years' therapy of type II diabetes: a progressive disease. U.K. Prospective Diabetes Study Group | Q56914456 | ||
| Selective β-Cell Loss and α-Cell Expansion in Patients with Type 2 Diabetes Mellitus in Korea | Q57214866 | ||
| Do Lifestyle Changes Reduce Serious Outcomes in Diabetes? | Q58039510 | ||
| Insulin glargine use and short-term incidence of malignancies—a population-based follow-up study in Sweden | Q61852798 | ||
| Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control | Q68123283 | ||
| Reinventing type 2 diabetes: pathogenesis, treatment, and prevention | Q80854053 | ||
| FDA places greater restrictions on access to rosiglitazone | Q85093658 | ||
| Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). | Q22241288 | ||
| Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 | ||
| Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 | ||
| Metformin monotherapy for type 2 diabetes mellitus | Q24246552 | ||
| Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies | Q24632655 | ||
| Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study | Q24654974 | ||
| Type 1 diabetes | Q27000491 | ||
| Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review | Q27023364 | ||
| Association of an intensive lifestyle intervention with remission of type 2 diabetes | Q27347992 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| US regulators relax restrictions on rosiglitazone | Q45255107 | ||
| Voglibose for prevention of type 2 diabetes mellitus: a randomised, double-blind trial in Japanese individuals with impaired glucose tolerance. | Q46036413 | ||
| Effects of Mitiglinide, a Short-Acting Insulin Secretagogue, on Daily Glycemic Variability and Oxidative Stress Markers in Japanese Patients with Type 2 Diabetes Mellitus | Q46133537 | ||
| Pancreatic beta-cell mass in European subjects with type 2 diabetes | Q46332814 | ||
| Effect of intensive insulin therapy on beta-cell function and glycaemic control in patients with newly diagnosed type 2 diabetes: a multicentre randomised parallel-group trial. | Q46576386 | ||
| The clinical and economic consequences of obesity | Q48086700 | ||
| Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance | Q51161029 | ||
| Predictors of remission of type 2 diabetes mellitus in obese patients after gastrointestinal surgery | Q51330421 | ||
| C-peptide and the risk for incident complications and mortality in type 2 diabetic patients: a retrospective cohort study after a 14-year follow-up | Q51356948 | ||
| Effect of obesity on declining beta cell function after diagnosis of type 2 diabetes: a possible link suggested by cross-sectional analysis | Q51364172 | ||
| Activation of oxidative stress by acute glucose fluctuations compared with sustained chronic hyperglycemia in patients with type 2 diabetes | Q51500191 | ||
| Postprandial serum C-peptide to plasma glucose ratio predicts future insulin therapy in Japanese patients with type 2 diabetes | Q51534382 | ||
| Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study | Q51562831 | ||
| UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. UK Prospective Diabetes Study (UKPDS) Group | Q51570043 | ||
| Mechanism of metformin action in obese and lean noninsulin-dependent diabetic subjects | Q51608165 | ||
| Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study | Q43074672 | ||
| Effect of nateglinide on the incidence of diabetes and cardiovascular events | Q43130181 | ||
| Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study | Q43181601 | ||
| Aace Comprehensive Diabetes Management Algorithm 2013 | Q43448145 | ||
| Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial | Q43606926 | ||
| Association between serum C-peptide levels and chronic microvascular complications in Korean type 2 diabetic patients | Q43713192 | ||
| Intermittent high glucose enhances apoptosis in human umbilical vein endothelial cells in culture | Q43762927 | ||
| Effects of selected antidiabetics on weight loss--a retrospective database analysis | Q43869483 | ||
| Contributions of Basal and Prandial Hyperglycemia to Total Hyperglycemia in Older and Younger Adults with Type 2 Diabetes Mellitus | Q43993057 | ||
| Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets | Q44320631 | ||
| Residual β-Cell Function and HLA-A24 in IDDM: Markers of Glycemic Control and Subsequent Development of Diabetic Retinopathy | Q44581658 | ||
| Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies | Q44698439 | ||
| Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin | Q44777896 | ||
| Acarbose slows progression of intima-media thickness of the carotid arteries in subjects with impaired glucose tolerance | Q44836881 | ||
| The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes | Q28273497 | ||
| Systematic review of the benefits and risks of metformin in treating obesity in children aged 18 years and younger | Q28304126 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes | Q29547541 | ||
| Effects of intensive glucose lowering in type 2 diabetes | Q29547736 | ||
| 10-year follow-up of intensive glucose control in type 2 diabetes | Q29615973 | ||
| Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes | Q29619192 | ||
| Glucose control and vascular complications in veterans with type 2 diabetes | Q29619213 | ||
| Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial | Q29619886 | ||
| Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy | Q29620534 | ||
| Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes | Q30548796 | ||
| Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria | Q31931889 | ||
| Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial | Q33425402 | ||
| Glycated albumin and glycated hemoglobin are influenced differently by endogenous insulin secretion in patients with type 2 diabetes | Q33602138 | ||
| Hypoglycemia, diabetes, and cardiovascular events | Q33873251 | ||
| Diabetes mellitus, fasting glucose, and risk of cause-specific death | Q33945937 | ||
| Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial | Q33999757 | ||
| Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis | Q34031108 | ||
| Intensive lifestyle intervention reduces urinary incontinence in overweight/obese men with type 2 diabetes: results from the Look AHEAD trial | Q34047087 | ||
| Clinical impact of glycated albumin as another glycemic control marker | Q34132286 | ||
| Rosiglitazone: a European regulatory perspective. | Q34154718 | ||
| The importance of first-phase insulin secretion: implications for the therapy of type 2 diabetes mellitus | Q34292419 | ||
| Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program | Q34312885 | ||
| Insulin Glargine and Cancer Risk in Patients with Diabetes: A Meta-Analysis | Q34320632 | ||
| Accurate assessment of beta-cell function: the hyperbolic correction | Q34508795 | ||
| The influence of glucose-lowering therapies on cancer risk in type 2 diabetes | Q34609508 | ||
| Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study. | Q34628009 | ||
| Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial | Q34766176 | ||
| Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: a systematic review and meta-analysis | Q34985373 | ||
| Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials | Q35024182 | ||
| Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes | Q35060170 | ||
| The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes | Q35085591 | ||
| Beta cell function following 1 year vildagliptin or placebo treatment and after 12 week washout in drug-naive patients with type 2 diabetes and mild hyperglycaemia: a randomised controlled trial | Q35091620 | ||
| Chronic Reduction of Fasting Glycemia With Insulin Glargine Improves First- and Second-Phase Insulin Secretion in Patients With Type 2 Diabetes | Q35179893 | ||
| Effects of exenatide on measures of β-cell function after 3 years in metformin-treated patients with type 2 diabetes | Q35179964 | ||
| Postprandial blood glucose predicts cardiovascular events and all-cause mortality in type 2 diabetes in a 14-year follow-up: lessons from the San Luigi Gonzaga Diabetes Study | Q35225468 | ||
| Pancreatic GLP-1 receptor activation is sufficient for incretin control of glucose metabolism in mice. | Q35640531 | ||
| Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naive patients with type 2 diabetes (DURATION-4): a 26-week double-blind study | Q35688369 | ||
| Effects of rosiglitazone, glyburide, and metformin on β-cell function and insulin sensitivity in ADOPT. | Q35797022 | ||
| Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study | Q36013549 | ||
| Use of thiazolidinediones and the risk of bladder cancer among people with type 2 diabetes: a meta-analysis | Q36247512 | ||
| Predicting the glycemic response to gastric bypass surgery in patients with type 2 diabetes. | Q36477817 | ||
| Safety, tolerability, and efficacy of metformin extended-release oral antidiabetic therapy in patients with type 2 diabetes: an observational trial in Asia | Q36546955 | ||
| Hypoglycemia and cardiovascular risks | Q36783714 | ||
| Effects of Metformin, Metformin Plus Rosiglitazone, and Metformin Plus Lifestyle on Insulin Sensitivity and β-Cell Function in TODAY | Q36868320 | ||
| Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial | Q37105140 | ||
| Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus | Q37141727 | ||
| Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes | Q37250961 | ||
| Cancer incidence among those initiating insulin therapy with glargine versus human NPH insulin | Q37278227 | ||
| Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group | Q37296839 | ||
| Cohort study of insulin glargine and risk of breast, prostate, and colorectal cancer among patients with diabetes. | Q37331188 | ||
| Effect of glucose variability on the long-term risk of microvascular complications in type 1 diabetes | Q37364903 | ||
| Insulin as an anti-inflammatory and antiatherogenic modulator | Q37380363 | ||
| Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. | Q37460057 | ||
| Clinical application of incretin-based therapy: therapeutic potential, patient selection and clinical use. | Q37493196 | ||
| The effects of gliclazide, metformin, and acarbose on body composition in patients with newly diagnosed type 2 diabetes mellitus | Q37502106 | ||
| Pathophysiologic approach to therapy in patients with newly diagnosed type 2 diabetes | Q37577162 | ||
| Effects of randomization to intensive glucose control on adverse events, cardiovascular disease, and mortality in older versus younger adults in the ACCORD Trial | Q37597008 | ||
| Preservation of β-Cell Function: The Key to Diabetes Prevention | Q37893344 | ||
| Insulin and atherosclerosis: How are they related? | Q38090864 | ||
| The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Type 2 Diabetes Mellitus | Q38112660 | ||
| SGLT inhibitors in management of diabetes | Q38195440 | ||
| The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice | Q38363214 | ||
| Use of thiazolidinediones and fracture risk | Q38456774 | ||
| Lower beta cell function relates to sustained higher glycated albumin to glycated hemoglobin ratio in Japanese patients with type 2 diabetes | Q39318051 | ||
| Trends in Antidiabetic Prescription Patterns in Japan From 2005 to 2011 | Q39418578 | ||
| Association between beta cell function and future glycemic control in patients with type 2 diabetes | Q39497871 | ||
| Postprandial serum C-peptide to plasma glucose ratio as a predictor of subsequent insulin treatment in patients with type 2 diabetes | Q39770734 | ||
| Urinary C-peptide as an index of unstable glycemic control in insulin-dependent diabetes mellitus (IDDM) | Q42009571 | ||
| Basal Insulin and Cardiovascular and Other Outcomes in Dysglycemia | Q42507791 | ||
| Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia | Q42767818 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 3 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 923-943 | |
| P577 | publication date | 2014-08-14 | |
| P13046 | publication type of scholarly work | review article | Q7318358 |
| P1433 | published in | Journal of Clinical Medicine | Q27724774 |
| P1476 | title | Importance of Beta Cell Function for the Treatment of Type 2 Diabetes | |
| P478 | volume | 3 |
| Q55232113 | Cardiovascular Autonomic Neuropathy and Glucose Variability in Patients With Type 1 Diabetes: Is There an Association? |
| Q38641910 | Effect of continuous positive airway pressure on glucose metabolism in adults with type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. |
| Q53678863 | Ethnic Similarities and Differences in the Relationship between Beta Cell Mass and Diabetes |
| Q34486820 | Glycemic variability and oxidative stress: a link between diabetes and cardiovascular disease? |
| Q90288982 | Relationship between Free Thyroxine and Islet Beta-cell Function in Euthyroid Subjects |
| Q91974155 | The role of macrophages in obesity-associated islet inflammation and β-cell abnormalities |
| Q27692665 | β-cell dysfunction: Its critical role in prevention and management of type 2 diabetes |
Search more.